Urteste develops diagnostic tests for more than ten of the most common cancers (breast, pancreatic, prostate, kidney, colorectal, liver, bile duct, stomach, lung, throat, ovary, uterus, blood and nervous system cancer). The company’s most advanced projects involve tests for pancreatic and prostate cancer. These projects involve pilot clinical trials. The projects use tests involving kidney, colorectal, liver, bile duct and lung cancer candidates for the trials have been selected. In other projects, works are carried out for the purposes of detecting and qualifying compounds for clinical trials.